Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study
Background: Earlier studies have indicated a relatively higher risk of occurring meningioma among female breast cancer survivors and have suggested that tamoxifen might decrease this risk. The present study evaluated whether tamoxifen use in breast cancer patients can reduce the risk of meningioma.M...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00674/full |
| _version_ | 1819260608154959872 |
|---|---|
| author | Li-Min Sun Cheng-Li Lin Cheng-Li Lin Sean Sun Chung Y. Hsu Zonyin Shae Chia-Hung Kao Chia-Hung Kao Chia-Hung Kao |
| author_facet | Li-Min Sun Cheng-Li Lin Cheng-Li Lin Sean Sun Chung Y. Hsu Zonyin Shae Chia-Hung Kao Chia-Hung Kao Chia-Hung Kao |
| author_sort | Li-Min Sun |
| collection | DOAJ |
| description | Background: Earlier studies have indicated a relatively higher risk of occurring meningioma among female breast cancer survivors and have suggested that tamoxifen might decrease this risk. The present study evaluated whether tamoxifen use in breast cancer patients can reduce the risk of meningioma.Methods: We designed a population-based cohort study by using data from the National Health Insurance system of Taiwan to assess this issue. Between January 1, 2000, and December 31, 2008, women with breast cancer and of age ≥20 years were included. They were divided into two groups: those who had not received tamoxifen therapy and those who had. The Cox’s proportion hazard regression analysis was conducted to estimate the effects of tamoxifen treatment and the subsequent meningioma risk.Results: We identified a total of 50,442 tamoxifen users and 30,929 non-tamoxifen users. Tamoxifen users had a borderline significantly lower overall risk of meningioma than non-tamoxifen users [adjusted hazard ratio (aHR) = 0.64, 95% confidence interval (95% CI) = 0.40–1.02]. A statistically significant difference was found in those patients with tamoxifen treatment duration longer than 1,500 days (aHR = 0.42, 95% CI = 0.19–0.91) or with cumulative dosage exceeding 26,320 mg (aHR = 0.44, 95% CI = 0.22–0.88). Furthermore, no statistically significant joint effect of aromatase inhibitors and tamoxifen on the occurrence of meningioma among breast cancer patients was seen.Conclusion: Tamoxifen users had a non-significantly (36%) lower risk of developing meningioma than did tamoxifen non-users; however, our data indicated that tamoxifen therapy is associated with a reduced meningioma risk for Taiwanese breast cancer patients receiving long duration or high cumulative dosage treatment with tamoxifen. |
| first_indexed | 2024-12-23T19:28:36Z |
| format | Article |
| id | doaj.art-bf979efddba84bcdb55031a176e88797 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-23T19:28:36Z |
| publishDate | 2019-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-bf979efddba84bcdb55031a176e887972022-12-21T17:33:59ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-06-011010.3389/fphar.2019.00674440462Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort StudyLi-Min Sun0Cheng-Li Lin1Cheng-Li Lin2Sean Sun3Chung Y. Hsu4Zonyin Shae5Chia-Hung Kao6Chia-Hung Kao7Chia-Hung Kao8Department of Radiation Oncology, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, TaiwanManagement Office for Health Data, China Medical University Hospital, Taichung, TaiwanCollege of Medicine, China Medical University, Taichung, TaiwanDepartment of Cardiovascular Science, Midwestern University, Glendale, AZ, United StatesGraduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, Taichung, TaiwanDepartment of Computer Science and Information Engineering, Asia University, Taichung, TaiwanGraduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, Taichung, TaiwanDepartment of Nuclear Medicine, China Medical University Hospital, Taichung, TaiwanDepartment of Bioinformatics and Medical Engineering, Asia University, Taichung, TaiwanBackground: Earlier studies have indicated a relatively higher risk of occurring meningioma among female breast cancer survivors and have suggested that tamoxifen might decrease this risk. The present study evaluated whether tamoxifen use in breast cancer patients can reduce the risk of meningioma.Methods: We designed a population-based cohort study by using data from the National Health Insurance system of Taiwan to assess this issue. Between January 1, 2000, and December 31, 2008, women with breast cancer and of age ≥20 years were included. They were divided into two groups: those who had not received tamoxifen therapy and those who had. The Cox’s proportion hazard regression analysis was conducted to estimate the effects of tamoxifen treatment and the subsequent meningioma risk.Results: We identified a total of 50,442 tamoxifen users and 30,929 non-tamoxifen users. Tamoxifen users had a borderline significantly lower overall risk of meningioma than non-tamoxifen users [adjusted hazard ratio (aHR) = 0.64, 95% confidence interval (95% CI) = 0.40–1.02]. A statistically significant difference was found in those patients with tamoxifen treatment duration longer than 1,500 days (aHR = 0.42, 95% CI = 0.19–0.91) or with cumulative dosage exceeding 26,320 mg (aHR = 0.44, 95% CI = 0.22–0.88). Furthermore, no statistically significant joint effect of aromatase inhibitors and tamoxifen on the occurrence of meningioma among breast cancer patients was seen.Conclusion: Tamoxifen users had a non-significantly (36%) lower risk of developing meningioma than did tamoxifen non-users; however, our data indicated that tamoxifen therapy is associated with a reduced meningioma risk for Taiwanese breast cancer patients receiving long duration or high cumulative dosage treatment with tamoxifen.https://www.frontiersin.org/article/10.3389/fphar.2019.00674/fullbreast cancermeningiomatamoxifenpopulation-based studycohort study |
| spellingShingle | Li-Min Sun Cheng-Li Lin Cheng-Li Lin Sean Sun Chung Y. Hsu Zonyin Shae Chia-Hung Kao Chia-Hung Kao Chia-Hung Kao Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study Frontiers in Pharmacology breast cancer meningioma tamoxifen population-based study cohort study |
| title | Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study |
| title_full | Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study |
| title_fullStr | Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study |
| title_full_unstemmed | Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study |
| title_short | Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study |
| title_sort | long term use of tamoxifen is associated with a decreased subsequent meningioma risk in patients with breast cancer a nationwide population based cohort study |
| topic | breast cancer meningioma tamoxifen population-based study cohort study |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00674/full |
| work_keys_str_mv | AT liminsun longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chenglilin longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chenglilin longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT seansun longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chungyhsu longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT zonyinshae longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chiahungkao longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chiahungkao longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy AT chiahungkao longtermuseoftamoxifenisassociatedwithadecreasedsubsequentmeningiomariskinpatientswithbreastcanceranationwidepopulationbasedcohortstudy |